AGA2118, a Bispecific Monoclonal Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and Led to Rapid BMD Gains in a First in Human, Single- and Multiple-Dose, Placebo-Controlled, Randomized Study

AGA2118 - Angitia Biopharma

https://asbmr.confex.com/asbmr/2024/meetingapp.cgi/Paper/1605

Matthew T. Drake, MD, PhD1; Richard Friend2; Yilong Zhang3; Juan Ke3; Yunfeng Li3; Manesha Lankachandra3; Ann C Zovein3; Hua Zhu Ke3; Willard Dere3; Ricardo Dent, MD3

Aug 5, 2024